Chromaderm, Inc.
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 685
- Registration Number
- NCT00604383
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT -5 hours, EST) or speak with your personal physician., Indianapolis, Indiana, United States
Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2007-11-01
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00552227
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 am to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States
Effect of LY333531 on Vascular and Neural Functions
- Conditions
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00482976
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States
Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2016-08-29
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00297401
- Locations
- 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physcian., Toronto, Ontario, Canada
Treatment for Completers of the Study B7A-MC-MBCM
- First Posted Date
- 2005-12-19
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 203
- Registration Number
- NCT00266695
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Madison, Wisconsin, United States
The Effect of Ruboxistaurin on Small Fiber Function
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT00190970
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Norfolk, Virginia, United States
Effect of Ruboxistaurin on Clinically Significant Macular Edema
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 309
- Registration Number
- NCT00133952
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
Reduction in the Occurrence of Center-Involved Diabetic Macular Edema
- First Posted Date
- 2004-08-31
- Last Posted Date
- 2016-10-06
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 731
- Registration Number
- NCT00090519
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom
Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes
- Conditions
- First Posted Date
- 2002-08-30
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Chromaderm, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00044408
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom
The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2002-08-21
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Chromaderm, Inc.
- Registration Number
- NCT00044148